- Home
- HKPD vs RNAZ Comparison
HKPD vs RNAZ Comparison
Compare HKPD & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HKPD | RNAZ |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HKPD | RNAZ |
|---|---|---|
| Price | $0.80 | $9.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | 50.7K | ★ 613.8K |
| Earning Date | 08-14-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,313,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.72 | N/A |
| 52 Week Low | $0.66 | $6.08 |
| 52 Week High | $2.76 | $316.28 |
Technical Indicators
Market Signals| Indicator | HKPD | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 48.21 |
| Support Level | $0.75 | $7.99 |
| Resistance Level | $0.89 | $11.08 |
| Average True Range (ATR) | 0.08 | 1.29 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 57.90 | 28.02 |
Price Performance
Historical ComparisonAbout HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.